ECSP055839A - COMPOSICIONES Y MÉTODOS PARA TRATAR LA ADMINISTRACIÓN MEJORADA POR VIA MUCOSA DE PÉPTIDOS FIJADORES AL RECEPTOR Y2 y MÉTODOS PARA TRATAR Y PREVENIR LA OBESIDAD - Google Patents

COMPOSICIONES Y MÉTODOS PARA TRATAR LA ADMINISTRACIÓN MEJORADA POR VIA MUCOSA DE PÉPTIDOS FIJADORES AL RECEPTOR Y2 y MÉTODOS PARA TRATAR Y PREVENIR LA OBESIDAD

Info

Publication number
ECSP055839A
ECSP055839A ECSP055839A ECSP055839A EC SP055839 A ECSP055839 A EC SP055839A EC SP055839 A ECSP055839 A EC SP055839A EC SP055839 A ECSP055839 A EC SP055839A
Authority
EC
Ecuador
Prior art keywords
methods
peptide
treat
administration
receiver
Prior art date
Application number
Other languages
English (en)
Inventor
Steven C Quay
Gordon Brant
Mary Kleppe
Conor J Macevilly
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/322,266 external-priority patent/US7166575B2/en
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of ECSP055839A publication Critical patent/ECSP055839A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

RESUMEN DE LA INVENCIÓN Se describen composiciones farmacéuticas y métodos que comprenden al menos un compuesto de péptido YY y no o más agentes para mejorarde la administración intranasal para una administración del péptido YY por vía mucosa nasal mejorada, para el tratamiento de una variedad de enfermedades y condiciones que incluyen la obesidad en sujetos mamíferos. En un aspecto, las formulaciones para la administración intranasal y los métodos proveen una administración mejorada del péptido YY en el plasma sanguíneo o en el tejido o fluido del sistema nervioso central (SNC), por ejemplo, produciendo un pico de concentración (Cmax) del péptido YY en el plasma sanguíneo o en el fluido o tejido del SNC del sujeto que es 20% o mayor comparado con el pico de concentración del péptido YY en el plasma sanguíneo o en fluido o tejido del SNC del sujeto tras la administración de una misma concentración o dosis de péptido YY por inyección subcutánea
ECSP055839 2002-12-17 2005-06-07 COMPOSICIONES Y MÉTODOS PARA TRATAR LA ADMINISTRACIÓN MEJORADA POR VIA MUCOSA DE PÉPTIDOS FIJADORES AL RECEPTOR Y2 y MÉTODOS PARA TRATAR Y PREVENIR LA OBESIDAD ECSP055839A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/322,266 US7166575B2 (en) 2002-12-17 2002-12-17 Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US49322603P 2003-08-07 2003-08-07
US50117003P 2003-09-08 2003-09-08
US51078503P 2003-10-10 2003-10-10
US51729003P 2003-11-04 2003-11-04
US51881203P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
ECSP055839A true ECSP055839A (es) 2006-03-01

Family

ID=32686401

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP055839 ECSP055839A (es) 2002-12-17 2005-06-07 COMPOSICIONES Y MÉTODOS PARA TRATAR LA ADMINISTRACIÓN MEJORADA POR VIA MUCOSA DE PÉPTIDOS FIJADORES AL RECEPTOR Y2 y MÉTODOS PARA TRATAR Y PREVENIR LA OBESIDAD

Country Status (13)

Country Link
US (4) US7186691B2 (es)
EP (1) EP1581245A2 (es)
JP (1) JP2006516262A (es)
AU (1) AU2003299722A1 (es)
BR (1) BR0316685A (es)
CA (1) CA2510199A1 (es)
CO (1) CO5700705A2 (es)
EA (1) EA008829B1 (es)
EC (1) ECSP055839A (es)
MA (1) MA27535A1 (es)
MX (1) MXPA05006572A (es)
NO (1) NO20053430L (es)
WO (1) WO2004056314A2 (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
EP1583549A4 (en) * 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050181456A1 (en) * 2004-02-09 2005-08-18 Nastech Pharmaceutical Company Inc. Methods for determining the amount of peptide YY in blood
EP2106790B1 (en) * 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
ATE519495T1 (de) * 2004-03-17 2011-08-15 7Tm Pharma As Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
JP5749879B2 (ja) * 2004-07-12 2015-07-15 エミスフェアー・テクノロジーズ・インク ペプチドｙｙおよびペプチドｙｙアゴニストの送達用組成物
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
SI1846546T1 (sl) * 2005-02-08 2011-07-29 Woodford Associates Ltd Alkoholna pijača, obogatena z 1H216O
EP1845805B1 (en) * 2005-02-08 2012-11-07 Woodford Associates Limited Non-alcoholic beverage enriched with 1h2 16o
EA012881B1 (ru) * 2005-03-05 2009-12-30 Сергей Павлович Соловьёв Косметическая композиция с повышенным содержаниемho
JP2008533005A (ja) * 2005-03-11 2008-08-21 ヴァーダ コンサルティング リミテッド 生物学的活性物質の皮内的、経皮的又は経粘膜的送達のための方法
EA012822B1 (ru) * 2005-03-11 2009-12-30 Вада Консалтинг Лимитед Композиции для дезинфекции поверхностей неодушевленных предметов
EA011143B1 (ru) * 2005-03-11 2009-02-27 Вада Консалтинг Лимитед Метод стимуляции роста волос и их регенерации
JP2008533003A (ja) * 2005-03-11 2008-08-21 ヴァーダ コンサルティング リミテッド 製薬用軽水、治療用組成物及びその方法
RU2275920C1 (ru) * 2005-04-01 2006-05-10 Игорь Анатольевич Помыткин Способ лечения новообразований
US20090054326A1 (en) * 2005-07-11 2009-02-26 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
US20080292719A1 (en) * 2005-12-12 2008-11-27 Igor Anatolievich Pomytkin Method of Treating Metabolic Syndrome
US20080292718A1 (en) * 2005-12-12 2008-11-27 Igor Anatolievich Pomytkin Method for Suppression Appetite and Food Intake
WO2007070563A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Stable solid forms of enterostatin
EP1973557A4 (en) * 2005-12-13 2010-03-03 Harkness Pharmaceuticals Inc NON-HYGROSCOPIC COMPOSITIONS OF ENTEROSTATIN
EP1973558A4 (en) * 2005-12-13 2009-12-23 Harkness Pharmaceuticals Inc METHODS OF TREATING OBESITY WITH ENTEROSTATIN
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
WO2007137163A2 (en) 2006-05-19 2007-11-29 Georgia Tech Research Corporation Abc transporter ligand
RU2301067C1 (ru) * 2006-06-19 2007-06-20 Сергей Павлович Соловьев Средство и способ для повышения половой активности человека
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
CA2657578A1 (en) * 2006-07-11 2008-01-17 Harkness Pharmaceuticals, Inc. Methods of treating obesity using satiety factors
US8324158B2 (en) 2006-07-14 2012-12-04 Georgia Tech Research Corporation Methods for inhibiting CLC-2 channel with GATX2
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US8889622B2 (en) * 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
JP2010538981A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 単独でまたはペプチドＧｌｙ−Ａｒｇ−Ｇｌｙ−Ａｓｐ−Ａｓｎ−Ｐｒｏ−ＯＨと組み合わせて用いる、治療剤としてのペプチドＨｉｓ−Ｓｅｒ−Ｌｅｕ−Ｇｌｙ−Ｌｙｓ−Ｔｒｐ−Ｌｅｕ−Ｇｌｙ−Ｈｉｓ−Ｐｒｏ−Ａｓｐ−Ｌｙｓ−Ｐｈｅの使用
US9938333B2 (en) * 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CA2758415C (en) 2008-04-14 2019-06-04 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US20110230399A1 (en) * 2008-11-25 2011-09-22 Bowen Richard L Methods for Treating Obesity Related Disease
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010105094A1 (en) 2009-03-11 2010-09-16 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2464365A2 (en) * 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
US8207651B2 (en) 2009-09-16 2012-06-26 Tyco Healthcare Group Lp Low energy or minimum disturbance method for measuring frequency response functions of ultrasonic surgical devices in determining optimum operating point
KR101026864B1 (ko) 2009-10-08 2011-04-12 (주)송호바이오메드 고 수용성 ２―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
JP5819949B2 (ja) 2010-06-10 2015-11-24 ミダテック リミテッド ナノ粒子フィルム送達システム
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
RU2476227C2 (ru) * 2011-04-14 2013-02-27 Ольга Георгиевна Мельникова Способ снижения избыточного веса
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
SG10201604653TA (en) 2011-12-11 2016-07-28 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
CN104363924B (zh) 2012-03-16 2018-04-17 约翰霍普金斯大学 用于递送hif‑1抑制剂的控制释放调配物
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
KR102246914B1 (ko) 2013-03-15 2021-04-30 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
ES2729970T3 (es) 2013-04-10 2019-11-07 Univ Copenhagen Péptidos derivados de neuropéptidos y
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US20170081366A1 (en) * 2015-09-22 2017-03-23 Kyungpook National University Industry - Academic Cooperation Foundation Novel Peptides for Preventing or Treating Bone Diseases and Use Thereof
MX2018005932A (es) 2015-11-12 2019-05-20 Graybug Vision Inc Microparticulas aglomerantes para terapia medica.
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
EP3625247A4 (en) * 2017-05-16 2021-03-24 The University of Chicago COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF PATHOGENIC FUNGAL INFECTIONS AND MAINTAINING MICROBIOMAL COMENSALISM
KR20200132852A (ko) * 2018-01-23 2020-11-25 길라 테라퓨틱스, 인코포레이티드 펩티드 yy 약학적 제형, 조성물, 및 방법
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN117979954A (zh) * 2021-09-22 2024-05-03 辉凌有限公司 促肾上腺皮质激素肽组合物及使用方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
DK0495187T3 (da) * 1991-01-15 1997-08-11 Hemosphere Inc Protein-nanomatricer og fremstillingsmetode.
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
WO1994001268A1 (en) * 1992-07-07 1994-01-20 Continental Pet Technologies, Inc. Method of forming multi-layer preform and container with low crystallizing interior layer
EP0678018B1 (en) 1993-01-06 2003-04-09 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0692971A4 (en) * 1993-03-29 1997-11-12 Univ Cincinnati PEPTID YY ANALOGS AND USES THEREFOR
SI9420051A (en) 1993-08-09 1996-12-31 Biomeasure Inc Chemical modified peptide derivatives, process for their preparation and their use in human therapy
US5696093A (en) * 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) * 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5912227A (en) * 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
KR19990014865A (ko) * 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6017897A (en) * 1995-06-07 2000-01-25 Pasteur Merieux Connaught Canada Nucleic acid respiratory syncytial virus vaccines
US5716643A (en) * 1995-06-07 1998-02-10 Hemosphere Inc. Large scale production of medicine coated crosslinked protein microspheres
FR2736265B1 (fr) * 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
CA2294494A1 (en) * 1997-06-05 1998-12-10 Richard C. K. Yen Fibrinogen-coated microspheres
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
IT1293088B1 (it) 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU9185598A (en) 1997-09-25 1999-04-12 Banyu Pharmaceutical Co., Ltd. Novel neuropeptide y receptor antagonists
IL137349A0 (en) 1998-01-29 2001-07-24 Kinerton Ltd Process for making absorbable microparticles
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US6017879A (en) * 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US7396809B1 (en) 1999-02-10 2008-07-08 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
BR0212985A (pt) * 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
JP4124734B2 (ja) 2001-11-26 2008-07-23 アスビオファーマ株式会社 経鼻吸収用医薬組成物
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
WO2003105763A2 (en) 2002-06-14 2003-12-24 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof

Also Published As

Publication number Publication date
WO2004056314B1 (en) 2005-09-29
US7157426B2 (en) 2007-01-02
JP2006516262A (ja) 2006-06-29
BR0316685A (pt) 2005-11-01
US20040157777A1 (en) 2004-08-12
MXPA05006572A (es) 2005-12-14
NO20053430L (no) 2005-09-15
US20040209807A1 (en) 2004-10-21
EA008829B1 (ru) 2007-08-31
WO2004056314A2 (en) 2004-07-08
WO2004056314A3 (en) 2005-03-31
US7186691B2 (en) 2007-03-06
NO20053430D0 (no) 2005-07-14
CO5700705A2 (es) 2006-11-30
US20070129299A1 (en) 2007-06-07
MA27535A1 (fr) 2005-09-01
AU2003299722A1 (en) 2004-07-14
US20070197437A1 (en) 2007-08-23
EA200501007A1 (ru) 2006-02-24
CA2510199A1 (en) 2004-07-08
EP1581245A2 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
ECSP055839A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR LA ADMINISTRACIÓN MEJORADA POR VIA MUCOSA DE PÉPTIDOS FIJADORES AL RECEPTOR Y2 y MÉTODOS PARA TRATAR Y PREVENIR LA OBESIDAD
CY1121330T1 (el) Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
EA200200111A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
KR19990044182A (ko) 말초 활성 통각과민 치료용 아편제
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
NO20015931L (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
BR0111002A (pt) Combinação de secretagogos do hormÈnio do crescimento e antidepressivos
BR9916432A (pt) Compostos de triazinona para o tratamento de doenças devido ao sarcosystis, neospora e ao toxoplasma
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
ES2187030T3 (es) Una nueva sal.
AR009756A1 (es) Composicion farmaceutica para usar en el tratamiento de enfermedades inducidas por el virus sincitial respiratorio
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
EA200400386A1 (ru) Фармацевтическая композиция, содержащая гамма-бутиробетаин
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
Obermayer Cocaine's Legacy in Western Dentistry
AR037932A1 (es) Imidazolidinas sustituidas, medicamentos y el uso de dichos compuestos para la preparacion de medicamentos